Achieving a very good partial response or better (VGPR+) after four cycles of treatment translated into increased overall survival, according to a study of 1,304 patients with newly diagnosed multiple myeloma (NDMM). Researchers found:

• In the entire cohort, greater absolute free light chain (FLC) differences, younger age, lower hemoglobin, and IgA myeloma were associated with achieving VGPR+ after 4 cycles.

• The effect was more pronounced among patients receiving novel agents, and immunomodulators in particular.

• In patients receiving proteasome inhibitors, higher creatinine, lower calcium, and greater FLC differences were associated with better response.

• In a landmark analysis at 4 months from diagnosis, achieving VGPR+ was associated with decreased risk of mortality (hazard ratio, 0.69).

Citation: Binder M, Rajkumar SV, Gertz MA, et al. Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma. [Published online ahead of print September 1, 2015]. Am J Hematol. doi: 10.1002/ajh.24107.